Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)
- PMID: 36509612
- DOI: 10.1016/j.clgc.2022.11.004
Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)
Abstract
Introduction: Germ-cell tumors (GCTs) are the most common malignancy in young men. There is a paucity of data on GCTs in developing countries. LACOG 0515 study aimed to evaluate clinical characteristics and treatment outcomes in patients with GCTs from Brazilian cancer centers.
Materials and methods: This is a retrospective cohort study evaluating male patients diagnosed with GCTs from 2000 to 2018 in 13 Brazilian hospitals. We described baseline characteristics, progression-free survival (PFS), and overall survival (OS).
Results: A total of 1232 patients were included, with a median age of 30 years. Histology was seminoma in 47.1% and non-seminoma GCT (NSGCT) in 52.9%. The primary tumor site was testis in 96.5%. At diagnosis, clinical stage I was present in 68.1% and 34.7% and clinical stages IS/II/III in 31.9% and 65.2% of patients with seminoma and NSCGT, respectively. Following orchiectomy, 55.2% of patients with clinical stage I were managed with surveillance. The 5-year disease-free survival rates among patients with stage I were 98.0% in seminoma and 92.3% in NSGCT, with 5-year OS of 99.6% and 97.6%, respectively. Among patients with advanced disease (IS, II, and III), the 5-year PFS were 88.7% in seminoma and 68.7% in NSGCT, with 5y-OS of 97.6% and 82.8%, respectively.
Conclusion: This is the largest Brazilian cohort of GCTs. Our results show a high rate of adjuvant chemotherapy in patients with clinical stage I. Although our data demonstrate slightly inferior PFS compared with the International Germ Cell Cancer Collaborative Group and other contemporary series, the OS rates were similar.
Keywords: Developing countries; Germ-cell tumors; Prognostic groups; Testicular cancer.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.Med Oncol. 2019 Feb 6;36(3):28. doi: 10.1007/s12032-019-1252-6. Med Oncol. 2019. PMID: 30725328
-
Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.JCO Glob Oncol. 2021 Jan;7:63-71. doi: 10.1200/GO.20.00473. JCO Glob Oncol. 2021. PMID: 33434070 Free PMC article.
-
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.Ann Oncol. 2017 Mar 1;28(3):576-582. doi: 10.1093/annonc/mdw648. Ann Oncol. 2017. PMID: 27993806
-
How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.World J Urol. 2022 Dec;40(12):2863-2878. doi: 10.1007/s00345-022-04009-z. Epub 2022 May 12. World J Urol. 2022. PMID: 35554637 Free PMC article.
-
[Urologic treatment of testicular germ cell cancer].Arch Esp Urol. 2002 Oct;55(8):927-36. Arch Esp Urol. 2002. PMID: 12455283 Review. Spanish.
Cited by
-
Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey.Medicina (Kaunas). 2025 May 22;61(6):951. doi: 10.3390/medicina61060951. Medicina (Kaunas). 2025. PMID: 40572639 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical